This site is intended for health professionals only!

Published on 31 January 2011

Share this story:
Twitter
LinkedIn

Pneumococcal vaccine for adults to be launched this year

teaser

A vaccine to protect against pneumonia and meningitis in adults is expected to be launched this year.

Pfizer is preparing to market Prevnar 13 – a vaccine widely used to protect infants and young children against pneumococcal bacteria – for adults in 2011.

The vaccine is set to dominate the pneumococcal market within the next decade, it is reported.

Pneumovax 23 could quickly be replaced as the gold standard for the primary immunisation of elderly and high-risk adults.

The anticipated market shake-up will leave only marginal roles for Prevnar 13’s competitors, it is reported.

Use of the quadrivalent meningococcal conjugate vaccine (MenACWY) is expected to be limited in the seven major markets.

The US are unlikely to recommend routine MenACWY vaccination of infants, and the vaccine will continue to play only a marginal role in Europe, unless a marked serogroup shift occurs.

 

 



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn